Marion Maetens

3.5k total citations
40 papers, 1.2k citations indexed

About

Marion Maetens is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Marion Maetens has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Marion Maetens's work include HER2/EGFR in Cancer Research (9 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer-related Molecular Pathways (7 papers). Marion Maetens is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer-related Molecular Pathways (7 papers). Marion Maetens collaborates with scholars based in Belgium, United States and Italy. Marion Maetens's co-authors include Jean‐Christophe Marine, Sarah Francoz, Sarah De Clercq, Guillermina Lozano, Franck Toledo, Geoffrey M. Wahl, Eric Bellefroid, Pascal Froment, Gilles Doumont and Sven Bogaerts and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Marion Maetens

34 papers receiving 1.2k citations

Peers

Countries citing papers authored by Marion Maetens

Since Specialization

Citations

This map shows the geographic impact of Marion Maetens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion Maetens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion Maetens more than expected).

Fields of papers citing papers by Marion Maetens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion Maetens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion Maetens. The network helps show where Marion Maetens may publish in the future.

Co-authorship network of co-authors of Marion Maetens

This figure shows the co-authorship network connecting the top 25 collaborators of Marion Maetens. A scholar is included among the top collaborators of Marion Maetens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marion Maetens. Marion Maetens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study 2025 ·Breast Cancer Research ·Karen Van Baelen, (unknown), François Richard, (unknown), Maria Margarete Karsten, Guilherme Nader Marta, Peter Vermeulen, Luc Dirix, (unknown), Evandro de Azambuja, Denis Larsimont, Marion Maetens, Elia Biganzoli, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Patrick Neven, Giuseppe Floris, Christine Desmedt	1
2	Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial 2024 ·Clinical Cancer Research ·Mattia Rediti, Danai Fimereli, (unknown), Zéna Wimana, David Venet, Patrick Flamen, Thomas Guiot, Elisabeth G.E. de Vries, Carolina P. Schröder, C. Willemien Menke‐van der Houven van Oordt, Marion Maetens, Samira Majjaj, Denis Larsimont, Françoise Rothé, Christos Sotiriou, Géraldine Gebhart	3
3	Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial 2024 ·Nature Communications ·Mattia Rediti, David Venet, (unknown), Marion Maetens, Delphine Vincent, Samira Majjaj, Sarra El-Abed, Serena Di Cosimo, Takayuki Ueno, Miguel Izquierdo, Martine Piccart, Lajos Pusztai, Sherene Loi, Roberto Salgado, G. Viale, Françoise Rothé, Christos Sotiriou	3
4	Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review 2024 ·Breast Cancer Research ·(unknown), Karen Van Baelen, Marion Maetens, Tatjana Geukens, (unknown), Ines Nevelsteen, Ann Smeets, (unknown), P. Neven, Stijn L.W. Koolen, Hans Wildiers, Kevin Punie, Christine Desmedt	6
5	Stromal Tumor-Infiltrating Lymphocytes in Hormone Receptor–Positive/HER2 Negative Metastatic Breast Cancer 2024 ·Modern Pathology ·(unknown), (unknown), Maxim De Schepper, Tatjana Geukens, Karen Van Baelen, Marion Maetens, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sigrid Hatse, P. Neven, Hans Wildiers, Elia Biganzoli, (unknown), François Richard, Giuseppe Floris, Christine Desmedt	0
6	Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium 2024 ·Modern Pathology ·Maxim De Schepper, Thijs Koorman, François Richard, Matthias Christgen, Anne Vincent‐Salomon, Stuart J. Schnitt, P. J. van Diest, (unknown), (unknown), Marion Maetens, Isabelle Vanden Bempt, Nadia Harbeck, Ulrike Nitz, (unknown), Sherko Kümmel, Oleg Gluz, Birgit Weynand, Giuseppe Floris, Patrick W.B. Derksen, Christine Desmedt	7
7	Adipocyte heterogeneity and tumor infiltration of adipose tissue in patients with metastatic breast cancer 2024 ·The Breast ·(unknown), (unknown), (unknown), Marion Maetens, François Richard, Maxim De Schepper, (unknown), (unknown), (unknown), Sophia Leduc, Karen Van Baelen, Sigrid Hatse, Tatjana Geukens, (unknown), Hans Wildiers, Patrick Neven, (unknown), Giuseppe Floris, Christine Desmedt	0
8	2MO Expression levels of immune checkpoint markers (IC) in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC) 2023 ·ESMO Open ·(unknown), (unknown), Maxim De Schepper, Tatjana Geukens, Karen Van Baelen, Marion Maetens, (unknown), (unknown), Bram Boeckx, (unknown), Kevin Punie, Patrick Neven, Hans Wildiers, W. Van den Bogaert, Elia Biganzoli, Diether Lambrechts, Gianluca Floris, François Richard, Christine Desmedt	1
9	14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status 2023 ·ESMO Open ·François Richard, Maxim De Schepper, Tatjana Geukens, Hanne Vos, Ayse Bassez, (unknown), Marion Maetens, Lili Wang, Ines Nevelsteen, Hans Wildiers, Patrick Neven, Kevin Punie, Ann Smeets, Diether Lambrechts, Giuseppe Floris, Christine Desmedt	0
10	Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target 2023 ·The Breast ·François Richard, Maxim De Schepper, Marion Maetens, Sophia Leduc, Edoardo Isnaldi, Tatjana Geukens, Karen Van Baelen, (unknown), Peter Vermeulen, Steven Van Laere, François Bertucci, Naoto T. Ueno, Luc Dirix, Giuseppe Floris, Elia Biganzoli, Christine Desmedt	6
11	Digital analysis of distant and cancer-associated mammary adipocytes 2020 ·The Breast ·Edoardo Isnaldi, François Richard, Maxim De Schepper, Delphine Vincent, Sophia Leduc, Marion Maetens, Tatjana Geukens, Giuseppe Floris, Ghizlane Rouas, Fátima Cardoso, Christos Sotiriou, Gabriele Zoppoli, Denis Larsimont, Elia Biganzoli, Christine Desmedt	8
12	Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome 2020 ·EBioMedicine ·David Venet, Danai Fimereli, Françoise Rothé, Bram Boeckx, Marion Maetens, Samira Majjaj, Ghizlane Rouas, Maria Capra, Giuseppina Bonizzi, (unknown), Christine Galant, Martine Piccart, Giancarlo Pruneri, Denis Larsimont, Diether Lambrechts, Christine Desmedt, Christos Sotiriou	25
13	SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) 2019 ·Annals of Oncology ·Christian Maurer, Daniel Eiger, (unknown), Philippe Aftimos, Marion Maetens, (unknown), Marianne Paesmans, Michail Ignatiadis, Martine Piccart, Laurence Buisseret	4
14	CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial 2019 ·BMC Cancer ·Françoise Rothé, Marion Maetens, Ghizlane Rouas, Marianne Paesmans, Marc Van den Eynde, Jean‐Luc Van Laethem, Philippe Vergauwe, (unknown), Yacine Barèche, Caroline Vandeputte, Michail Ignatiadis, Alain Hendlisz	14
15	Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial 2018 ·Annals of Oncology ·Michail Ignatiadis, Mariana Brandão, Marion Maetens, Noam Pondé, Samuel Martel, Stylianos Drisis, Isabelle Veys, (unknown), (unknown), Patrick Neven, François P. Duhoux, Jacques Chapiro, Ahmad Awada, Tatiana Besse‐Hammer, Marianne Paesmans, Martine Piccart, Peter Vuylsteke, Christos Sotiriou	0
16	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer 2014 ·Annals of Oncology ·Françoise Rothé, (unknown), Diether Lambrechts, (unknown), Delphine Vincent, Marion Maetens, Debora Fumagalli, Stefan Michiels, Stylianos Drisis, Carine Moerman, (unknown), Denis Larsimont, Ahmad Awada, Martine Piccart, Christos Sotiriou, Michail Ignatiadis	188
17	Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology 2014 ·BMC Genomics ·Debora Fumagalli, Alexis Blanchet-Cohen, David N. Brown, Christine Desmedt, David Gacquer, Stefan Michiels, Françoise Rothé, Samira Majjaj, Roberto Salgado, Denis Larsimont, Michail Ignatiadis, Marion Maetens, Martine Piccart, Vincent Detours, Christos Sotiriou, Benjamin Haibe‐Kains	42
18	Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells 2009 ·Nucleic Acids Research ·Omar Nyabi, (unknown), Katharina Haigh, Agnieszka Gembarska, Steven Goossens, Marion Maetens, Sarah De Clercq, Benjamin Drogat, Lieven Haenebalcke, Sonia Bartunkova, (unknown), Bram De Craene, Mansour Karimi, Geert Berx, András Nagy, Pierre Hilson, Jean‐Christophe Marine, Jody J. Haigh	91
19	Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 2006 ·Cell Death and Differentiation ·Jean‐Christophe Marine, Sarah Francoz, Marion Maetens, Geoffrey M. Wahl, Franck Toledo, Guillermina Lozano	281
20	Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo 2006 ·Proceedings of the National Academy of Sciences ·Sarah Francoz, Pascal Froment, Sven Bogaerts, Sarah De Clercq, Marion Maetens, Gilles Doumont, Eric Bellefroid, Jean‐Christophe Marine	210

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact